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Abstract
The purpose of this phospho-proteomics
study was to demonstrate the broad analysis of
cellular protein phosphorylation in cells and
tissue as a means to monitor changes in cellular
states. As a cancer model, human tumor-derived
A431 cells known to express the epidermal
growth factor receptor (EGFR) were grown as
cell cultures or xenograft tumors in mice. The
cells and tumor-bearing animals were subjected
to treatments including the EGFR-directed pro-
tein kinase inhibitor PK166 and/or EGF stimu-
lation. Whole cell/tissue protein extracts were
converted to peptides by using trypsin, and
phosphorylated peptides were purified by an
affinity capture method. Peptides and phospho-
rylation sites were characterized and quantified
by using a combination of tandem mass spec-
troscopy (MS) and Fourier transform MS instru-
mentation (FTMS). By analyzing roughly 106 cell
equivalents, 780 unique phosphopeptides from
approx 450 different proteins were character-
ized. Only a small number of these phosphory-
lation sites have been described previously in
literature. Although a targeted analysis of the
EGFR pathway was not a specific aim of this
study, 22 proteins known to be associated with
EGFR signaling were identified. Fifty phospho-
peptides were found changed in abundance as a
function of growth factor or drug treatment
including novel sites of phosphorylation on the
EGFR itself. These findings demonstrate the fea-
sibility of using phospho-proteomics to deter-
mine drug and disease mechanisms, and as a
measure of drug target modulation in tissue.
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Introduction
The wide range of cellular processes that are
known to involve protein phosphorylation as
central elements of their regulation suggest
that a clearer picture of these events would be
valuable in understanding cellular physiology.
Recent reports have highlighted several tech-
niques demonstrating, to various degrees, an
ability to broadly catalog many protein phos-
phorylation sites (1–3). We have employed a
modified immobilized metal affinity chro-
matography (IMAC) approach first reported
by Ficarro et al. (1) in a series of differential
analyses to identify phosphorylation events
that occur following treatment of A431 cells
with epidermal growth factor (EGF) or the
EGF receptor (EGFR)-directed protein kinase
inhibitor, PKI166. By analyzing sample aliquots
representing roughly 106 cell equivalents, 780
unique phosphopeptides from approx 450 dif-
ferent proteins were characterized. In these
phosphoproteins, all three phospho-amino
acids were observed in their expected physio-
logical ratios—the great majority being phos-
phoserines. Only a small number of these
phosphorylation sites have been described pre-
viously in the literature. Whereas a targeted
analysis of the EGFR pathway was not a spe-
cific aim of this study, 22 proteins from the
EGFR pathway were identified as being phos-
phorylated, including six sites of phosphoryla-
tion on the EGFR itself. Three novel sites of
phosphorylation were identified on the EGFR,
two of which were differentially phosphory-
lated in response to EGF and PKI166 treat-
ment. Using a custom-built Fourier transform
mass spectrometer (FTMS), approx 350 phos-
phopeptides were quantified in terms of their
relative abundance as a function of growth
factor and drug treatment. Fifty of these pep-
tides were found to be differentially phospho-
rylated by a significant amount, including
differential phosphorylation on the EGFR as
noted above. Overall, the results that we report
provide a representative subset of the phos-
phoproteome that responds to PKI166 treat-
ment and is involved in EGFR signaling and
further validates the utility of this approach for
identifying phosphorylation sites and their
involvement in both physiological and patho-
physiological processes.
The general schema for differential phos-
phoprofiling is depicted in Fig. 1. Protein is
extracted from cell or tissue lysates and digested
with trypsin. Acidic residues are derivatized to
form d0 or d3 labeled methyl esters. For protein
identification the individual samples are sub-
jected to IMAC to isolate phosphopeptides and
analyzed with a 4 h liquid chromatography
(LC) gradient on a Q-Star Pulsar using a data
dependent tandem mass spectrometry (MS/
MS) algorithm. The data are then searched
against public databases using Mascot to iden-
tify peptide sequences, sites of phosphorylation,
and tentative protein IDs. These data are then
manually checked for added veracity.
For determining relative abundance between
two samples, differentially labeled samples are
pooled prior to IMAC isolation of phospho-
peptides and subsequent analysis is performed
on a custom-built 7T FTMS. Differentially
labeled pairs are identified based on their mass
difference of a multiple of three and relative
abundance is expressed as a ratio. Phospho-
peptide identities are then assigned to specific
differential ratios based on alignment of the
elution times of abundant marker proteins.
The EGF pathway was chosen to demon-
strate the utility of this approach to pharma-
ceutical research. Overexpression of the EGFR
was described to be associated with nonsmall
cell lung carcinomas and brain, bladder,
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breast, and ovarian carcinomas (4–8). Deregu-
lation (constitutive activation) of EGFR is also
associated with tumorigenesis and progression
(9). ErbB2, most closely related to EGF-R, is
overexpressed in approx 25% of primary
breast and ovarian tumors; ErbB2 overexpres-
sion in these two tumor types correlates with
earlier relapse and poor prognosis (10,11). A
number of therapeutic strategies aimed at
blocking EGFR activity have been pursued,
the most advanced of which include extracel-
lularly directed antibodies that block ligand
binding, Cetuximab (Erbitux) and ABX-EGF,
and small molecule ATP-competitive antago-
nists, Iressa (12), and Tarceva (13). 
PKI166 is a substituted pyrrolo[2,3-d]pyrim-
idine and is another ATP-competitive EGFR
inhibitor, which exhibits dual inhibition of
EGFR and erbB-2 (IC50 = 1 and 11 nM, respec-
tively) (14–16). PKI-166 has shown significant
and dose-dependent in vivo anti-tumor activ-
ity in several EGFR expressing xenograft
models in nude mice following oral adminis-
tration of 10–100 mg/kg/d(17). Complete and
long-lasting inhibition of EGF-stimulated
EGFR autophosphorylation in tumors was
observed following administration of a single
100 mg/kg oral dose (18). This study exam-
ines the effect of EGF and PKI166 on the phos-
phoprofile of the epidermoid tumor-derived
A431 cell line in culture and in xenograft
tumors grown in nude mice.
Results
Four samples were prepared from both cul-
tured cells and dissected tumors, treated and
analyzed as indicated in Table 1.
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Fig. 1. Schematic of workflow for cell/animal protocols, sample preparation, and peptide and data analysis.
Dashed lines show where data from one process was matched to the other to allow identification of quanti-
fied phosphopeptides.
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The results from the phosphopeptide identi-
fication analyses are summarized in Table 1. It is
important to note that these statistics are based
solely on those peptides that were selected (by
the MS software) for sequencing and found to
have a confirmed sequence from the Mascot
search. Roughly equal numbers of phosphory-
lation sites were identified from in vivo samples
as were found the cell culture samples.
The ratio of the different phosphoamino
acids (pS to pT to pY) is very similar between
all samples and is consistent with expected
physiological ratios. In total, 780 unique phos-
phopeptides were sequenced and identified
from 441 different proteins. Quantitation ratios
for 354 unique phosphopeptides from 117 dif-
ferent proteins were generated by matching
differentially labeled pairs from the FTMS
analysis to corresponding MS/MS data from
the Q-Star analysis. 
Routinely, greater than 95% of the peptides
identified after the modified IMAC enrich-
ment procedure are determined to be phos-
phorylated. Many more differentially labeled
pairs are observed in the FTMS analysis than
can be matched to Q-Star identifications, sug-
gesting that these numbers still represent just
a small percentage of the phosphopeptides. 
A diverse array of proteins were determined
to be phosphorylated, including: signaling
molecules, kinase, phosphatases, transcription
factors, proteins involved in differentiation
and apoptosis, RNA processing proteins, and
metabolic enzymes (Table 2). Each protein on
this list was identified by MS/MS sequenc-
ing of at least one phosphopeptide with a
sequence that matches a tryptic peptide within
the protein. In many cases multiple phospho-
rylation sites were identified for each protein.
For example, six sites of phosphorylation were
identified within the EGFR itself, including
three novel phosphoserine sites. 
Whereas the actual identification of any
specific phosphoprotein is a statistical event
dependent upon selection by the MS software
algorithm for sequencing, the numbers of pro-
teins identified per class should be roughly
proportional to their diversity, abundance, and
phosphorylation status. Thus, the representa-
tion of phosphoproteins uniquely identified in
the cell line samples compared to the tumor
samples (Table 2) highlights the greater rep-
resentation of desmosomal and gap junc-
tion phosphoproteins in the tumor cells. This
observed difference can be postulated to
reflect the morphology of a solid tumor com-
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Table 1
Treatment, Labeling, and Differential Analysis Performed for Each Sample*
*Samples T(1-4) are from tumors and C(1-4) are from cultured cells (see Experimental Protocol for details).
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pared to a monolayer of cultured cells, and
provides an example to support the notion
that broad phosphoprotein analysis offers the
potential of an unbiased view of the physio-
logical status of a cell or tissue.
Because we compared cell states ±EGF or
±PKI166, we cataloged the phosphoproteins
identified that have a known connection to the
EGFR signaling pathway (Table 2). Approxi-
mately 22 proteins that are known to be asso-
ciated with EGFR signaling were determined
to be phosphorylated in at least one sample
(shown in bold). This includes EGFR itself
and several downstream kinases such as Abl,
Pak2, PDK1, and RSK. Eight of these proteins
were determined to be differentially phos-
phorylated in response to EGF and/or PKI166
treatment.
Phosphoprotein Profiling of Tumor Cells _________________________________________________________ 73
Table 2
Proteins Identified to be Phosphorylated in A431 Cell Cultures (In Vitro)
or in A431 Tumors Grown as Xenografts in Nude Mice (In Vivo)
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Peptides that were determined to be signif-
icantly differentially phosphorylated in at least
one of the cell line comparisons are listed in
Table 3. A number of phosphopeptides are
observed to be more abundant in EGF treated
(+) vs untreated (–) A431 cells. Specifically, an
EGFR peptide containing two novel phospho-
serines is eightfold more abundant in EGF
treated cells, while 300 nM PKI166 (cell 2)
inhibited formation of this phosphopeptide by
a factor of 4, suggesting that regulation of S967
and S971 phosphorylation is stimulated by
EGF and inhibited by PKI166. Because PKI166
is a relatively selective EGFR inhibitor, the
observed inhibition of phosphorylation of
these sites is probably a result of inhibition of
EGFR pathways leading to activation of serine
kinases and/or serine phosphatases, rather
than direct effects on those enzymes.
This same peptide was found to be phos-
phorylated on tyrosine, corresponding to
EGFR Y974, after treatment with EGF. No
signal was detected for this phosphopeptide
in the absence of EGF treatment; therefore, the
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Table 3
Differentially Phosphorylated Peptides in In Vitro A431 Samples
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differential ratio is recorded as greater than
the difference between the signal observed in
‘+’ (d3 label) and the background level. 
The largest finite difference measured was
that of ribosomal protein S6. With almost a
10-fold increase in EGF treated vs nontreated
and over a 400-fold increase in cells treated with
EGF alone compared to those treated with
EGF and 300 nM PKI166 (Table 3), phospho-
rylation of this peptide is clearly affected by
the status of EGFR signaling and modulation
by PKI166. The three phosphorylation sites
identified on this peptide correspond to phos-
phorylation sites on ribosomal protein S6
known to correlate with activation of protein
synthesis (19,20). 
To highlight one complication of quantify-
ing phosphopeptides, it should be pointed out
that a related phosphopeptide from RPS6 was
determined to be >10-fold more abundant
in PKI166 treated cells than in cells treated
with EGF alone (differential ratio of 0.07).
Because this peptide contains two of the same
phosphoserines as the peptide described
above (pS236 and pS240), this data would
appear to be contradictory. However, upon
careful inspection this data is consistent with
the expected pattern of EGF stimulation of
RPS6 phosphorylation and inhibition of RPS6
phosphorylation by PKI166. Briefly, the RPS6
phosphopeptide carrying two phosphosites is
decreased because of increased phosphoryla-
tion of a third serine (pS235). This third phos-
phorylation also results in a change in the
trypsin cleavage site.
ADAM 17 (A disintegrin and metallopro-
teinase domain 17) also known as TNF-α con-
verting enzyme (TACE) has multiple splice
variants. One splice variant lacks residues
656...827, we found S786 to be phosphorylated,
thereby identifying the presence of the long
splice variant. TACE regulates EGFR ligand
availability in vivo (21). We found phosphory-
lation of S786 to be inhibited in the presence
of EGF. This suggests the possibility of a novel
mechanism regulating TACE mediated pro-
duction of EGFR ligands through a feedback
mechanism.
Cdc2-related kinase 7 (Crk7) also called
CDC2 related kinase with an arginine/serine-
rich (RS) domain (CrkRS), is a 1490 amino acid
protein that contains RS domains similar to
that of RNA splicing factors and co-localizes
with a hyperphosphorylated form of RNA
Polymerase II in cells and phosphorylates RNA
Polymerase II in vitro (22). Thus Crk7 may
be a link between transcription and splicing
machinery. In this study, phosphorylation of
Crk 7 on S477, was inhibited by a factor of 3.84
by 300 nM PKI166 treatment. S477 is located
within a PEST-like sequence suggesting a pos-
sible role for this phosphorylation in regulat-
ing Crk7 degradation in response to EGF. 
CDC2-Like kinase 5 (CDC2L5) or CDC2
Related Kinase 5 (Crk5) is the full-length amino
acid sequence of the cholinesterase-related cell
division controller (CHED) kinase, a previously
published partial coding sequence23. This
ubiquitous nuclear protein, shares a PITAVRE
and PITAIRE motif with other Cdc2-related
proteins. Antisense-CHED treatment impairs
growth and/or differentiation of hematopoi-
etic cells (megakaryocytes), indicating that
CHED is a positive growth/differentiation reg-
ulator (24). The kinase domain of CDC2L5 is
89% identical to Crk7 and it also contains a
Ser-Arg-rich (RS) domain that may play a role
in nuclear localization of the protein. Serines
395, 397, and 400 are localized in the middle
of the RS-rich sequence in CDC2L5. Increased
phosphorylation of these serines, upon stimu-
lation with EGF, may affect the nuclear target-
ing necessary for execution of CDC2L5’s role
in mitotic regulation.
Protein tyrosine phosphatase receptor type f
polypeptide (PTPRF) or interacting protein
Phosphoprotein Profiling of Tumor Cells _________________________________________________________ 75
Clinical Proteomics _______________________________________________________________ Volume 1, 2004
(liprin), α-1(PPFIA1), is a member of a recep-
tor PTPase interacting family that binds to
type f receptors such as leukocyte common
antigen-related protein (LAR). PPFIA1 binds
to the LAR membrane-distal D2 protein tyro-
sine phosphatase domain and appears to
localize LAR to focal adhesions. Both LAR and
PPFIA1 decorate the ends of focal adhesions
most proximal to the cell nucleus and are
excluded from the distal ends of focal adhe-
sions, thus localizing to regions of focal adhe-
sions presumably undergoing disassembly.
Therefore, LAR and PPFIA1 may regulate the
disassembly of focal adhesions and thus help
orchestrate cell-matrix interactions. Increased
phosphorylation of PPFIA1 in the presence of
300 nM PKI166 is consistent with the large
body of literature claiming a role for EGF sig-
naling in down regulating focal adhesions and
thereby stimulating tumor invasion (25,26).
The two phosphopeptides from the tumor
extracts determined to be increased with EGF
treatment are from Keratin (Krt1) and desmo-
plakin (DSP) (Table 4). Significantly, the tumor
T3:T4 comparison demonstrated higher lev-
els of phosphorylation of many desmosomal
and cytoskeletal proteins (DSP, Keratins, and
Plakophilins) in tumors from mice treated with
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Table 4
Differentially Phosphorylated Peptides Identified From A431 Tumor Samples 
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PKI166 for 1 h (T3) as compared to those treated
for 24 h (T4). Similarly EMS1 (Cortactin) and
catenin D1 (CTNND1) were shown to have
higher levels of phosphorylation at the earlier
time point. These data suggest that while EGFR
itself may be maximally inhibited at 1 h (data
not shown), the inhibition of downstream events
affecting the cytoskeleton and gap junctions/
desmosomes lags behind. Maximal inhibition of
these events may require transcriptional regula-
tion, protein turnover, and/or other processes
that would follow a different time course than
EGFR autophosphorylation. 
Cortactin plays a role in regulating cortical
actin assembly, transmembrane receptor orga-
nization and membrane dynamics. Aberrant
regulation of cortactin levels contributes to
tumor cell invasion and metastasis (27). EGF-
stimulation increases phosphorylation of cor-
tactin two-fold on Ser/Thr residues. Mek
activation is necessary and sufficient for EGF-
induced phosphorylation of Cortactin (28). In
this study, we found increased phosphoryla-
tion of Cortactin on S368 upon EGF stimula-
tion and reduced phosphorylation following
treatment with PKI166 in vitro (Table 4). These
data are consistent with disruption of the
EGFR-MEK-Erk pathway leading to cortical
actin rearrangements by PKI166. In vivo phos-
phorylation of S380 was elevated in 1 h
PKI166-treated mice compared to 24 h post-
PKI166 delivery. The time course of phospho-
regulation of this protein mirrors that of the
cytoskeletal and desmosomal proteins identi-
fied consistent with its involvement in regulat-
ing actin assembly and membrane dynamics.
P120 Catenin delta 1 (p120ctn) is implicated
both in cell transformation by Src and in
ligand-induced receptor signaling through the
EGF, PDGF, CSF-1 and Erbb2 receptors (29).
The association of catenins to cadherins pro-
duces a complex which is linked to the actin
filament network, and which seems to be of
primary importance for cadherins cell-adhe-
sion properties (30). Consistent with a role in
EGF-induced signaling, three phosphoserines
in p120ctn were found to be differentially reg-
ulated in the T3T4 comparison. 
This study has further highlighted the util-
ity of the IMAC phosphoprofiling method to
catalog large numbers of cellular phosphory-
lation events. Furthermore, with the addition
of the d0/d3 methyl ester labeling step, this
method can be used to analyze relative abun-
dance of phosphorylations in different cell
states. Significantly, this report is the first to
demonstrate the utility of this approach to
assess in vivo phosphorylation events. 
Overall, this approach offers a novel means
to analyze protein function and/or drug inter-
actions in an unbiased way. By taking a global
snapshot of a large number of phosphory-
lation events, effects of protein function or
drugs can be observed without guessing
which pathways you expect might be altered.
Once data from such a global analysis has
been achieved then more targeted approaches,
such as co-immunoprecipitations, can be done
to obtain more detailed information within
affected pathways.
Experimental Protocol
In Vitro A431 Samples
1 × 107 A431 cells (confluent monolayer in
75 mm dishes: approx 2 × 106 cells per 75 mm
dish) were starved for 16 h in medium con-
taining 1% fetal bovine serum (FBS), treated
for 60 min with EGF (50 ng/mL) in the pres-
ence or absence of PKI166 (300 nM, 3000 nM).
Cells were preincubated for 30 min with
PKI166 prior to treatment with EGF. 
In Vivo A431 Tumor Xenografts
The A431 epidermoid cell line (obtained from
the American Type Culture Collection [CRL
1555]) was used to establish sc tumors in female
BALB/c nu/nu (nude) mice according to a
previously described method (18) and tumors
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were grown to between 400 and 600 mg in
mass. Based upon previous pharmacokinetic
determinations PKI166-treated mice received
100 mg/kg po whereas control mice received
vehicle (four mice per group). Mice were then
sacrificed at 0 h, 1 h, and 24 h after cessation of
treatment. Five minutes before sacrifice, the
mice were administered 0.5 µg EGF/g body
weight iv; a group of vehicle-treated control
mice received 0.2 mL 0.9% w/v NaCl instead
of EGF. The tumors were dissected free of
necrotic material and then divided into halves,
snap-frozen in liquid nitrogen and stored at
–80°C. 
Lysis and Protein Extraction
Cells or tumors were lysed and total protein
extracted by using 1 mL of TRIzol Reagent
(Invitrogen) per 107 cells or 5:1 vol:wt in the
case of tumors. RNA and DNA were removed
by ethanol precipitation and protein was col-
lected by isopropanol precipitation. Protein
pellets were washed with 0.3M guanidine-HCl
in ethanol prior to protein solubilization and
analysis. Tryptic digests of protein samples
were derivatized in the presence of either d0
or d3 methanol as a means to differentially
mass-label peptides, as indicated in Table 1. By
this approach, labeled peptide mixtures were
combined prior to mass spec analysis, and
identical peptides differing by 3 daltons (per
esterified methyl group) were identified and
quantified for relative abundance. 
Sample Preparation
Sample preparation followed the procedure
of Ficarro et al. (1). Briefly, the Trizol protein
pellets were solubulized in 1% sodium dode-
cyl sulfate (SDS) and diluted to 0.2% SDS in
digest buffer for digestion overnight with
trypsin. The digests were taken to dryness and
methyl esters were made using d0 or d3
methanol, as listed in Tables 1 and 2. After
esterification the samples were aliquoted and
taken to dryness. Aliquoted samples were
stored at –80°C for future use.
IMAC Enrichment
IMAC enrichment followed the procedure
of Ficarro et al. (1). Each sample was subjected
to IMAC phosphopeptide enrichment. A metal
chelating microcapillary column was washed
with ethylene diamine tetraaccetic acid
(EDTA) and then charged with iron. The
column was acidified and the digested sample
was loaded to allow the phosphopeptides to
remain on the column. Organic washes were
used to remove non-phosphorylated peptides
and the phosphopeptides were eluted onto a
C-18 precolumn with a phosphate wash.
Qualitative MS analysis
The precolumn was attached to a C-18 ana-
lytical column with an emitter tip. The whole
column is connected to an Agilent 1100 HPLC
such that peptides were eluted in to the Sciex
Qstar Pulsar mass spectrometer. For a qualita-
tive look at the phosphopeptides present in a
sample we used a 4 h HPLC gradient where
solvent A was 0.2M acetic acid (HOAc) and
solvent B was 0.2M HOAc in 70% acetonitrile
(MeCN). The mass spectrometer is set to
acquire MS/MS spectra on the top three most
abundant ions in a MS scan. Once a mass is
subjected to MS/MS it is placed on an exclu-
sion list for 1 min to allow lesser abundant
ions to be selected for MS/MS analysis.
Qualitative Data Analysis
All MS/MS spectra were searched against
human-nr database using the Mascot search
algorithm. The correct methyl ester, d0 or d3,
was used as a static modification and differen-
tial modifications of phosphorylated Ser, Thr,
and Tyr were used as search parameters. All
MS/MS identifications were visually inspected
and those deemed correct were added to a
phosphopeptide list for each sample.
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Quantitative MS Analysis
For quantitative analysis another IMAC
enrichment was performed, except that two
samples were mixed, one d0 and one d3
labeled sample, and then loaded onto the
IMAC column for phospho enrichment. All of
the peptides were eluted onto a precolumn
and eluted into the mass spectrometer. Either
the FTMS or the QStar Pulsar was used for this
experiment. A custom-built 7T FTMS was used
for this study. During gradient elution of the
peptides the ions are accumulated in an exter-
nal quadrupole and then are pulsed into the
trap. Ions are detected for approx 100 ms/s
scan event. The current FTMS only produces
MS information during the 1 h HPLC gradient.
The QStar Pulsar was set to acquire one MS
and one MS/MS spectra during a 4 h gradient.
All quantitative data is analyzed manually and
with software developed at MDS Proteomics. 
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